Dupixent gains chronic spontaneous urticaria indication in Europe
The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.
Therapy Area
Eli Lilly flies the pharma flag in tech-heavy $1tn market cap club
“Reckless and harmful”: experts weigh in on CDC’s autism-vaccine link stance
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
Regeneron’s Eylea franchise boosted by pair of FDA approvals
Pfizer and Tris reach settlement with Texas over ADHD drug allegations
Arrowhead nets first commercial win as siRNA drug garners FDA approval
CSL to pump $1.5bn into US plasma supply chain
